Research programme: psoriasis therapeutics - Malvern Cosmeceutics

Drug Profile

Research programme: psoriasis therapeutics - Malvern Cosmeceutics

Alternative Names: MCL 007-01

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Malvern Cosmeceutics
  • Class
  • Mechanism of Action NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Psoriasis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Psoriasis in United Kingdom (Topical, Gel)
  • 16 Jul 2016 No recent reports of development identified for research development in Psoriasis in United Kingdom (PO, Tablet)
  • 28 May 2013 Early research in Psoriasis in United Kingdom (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top